Ferring Pharmaceuticals and Gilead Sciences have petitioned the FDA to change how market exclusivity is granted for combination drugs. The agency grants five years' exclusivity if all active compounds in a combination drug are new and three years' exclusivity otherwise. The drugmakers say combination drugs are the same as new drugs and should be treated accordingly.

Full Story:

Related Summaries